SRT1720 further preserved midbrain SNpc DAergic TH and PGC-1α levels and motor function in our in vivo PD model, suggesting SRT1720-or SIRT1-targeting drugs as novel therapeutics for treating PD [43]. This evidence concerns the gene PPARGC1A and Parkinson disease.